- Home
- LXRX
as 05-30-2025 4:00pm EST
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 228.8M | IPO Year: | 2000 |
| Target Price: | $3.67 | AVG Volume (30 days): | 4.1M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $2.45 | Next Earning Date: | 05-13-2025 |
| Revenue: | $31,213,000 | Revenue Growth: | 1251.21% |
| Revenue Growth (this year): | -68.36% | Revenue Growth (next year): | 46.60% |
Latest Lexicon Pharmaceuticals Inc. News
LXRX Breaking Stock News: Dive into LXRX Ticker-Specific Updates for Smart Investing
Investopedia
2 days ago
Ulta Stock Jumps as Beauty Product Spending Continues
GlobeNewswire
2 days ago
Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy
GlobeNewswire
2 days ago
Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
Benzinga
2 days ago
Northrop Grumman Raises $1 Billion Via Debt
GlobeNewswire
2 days ago
Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy
Newsfile
2 days ago
Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025
GlobeNewswire
2 days ago
TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast
GlobeNewswire
2 days ago
The York Water Company Files a Rate Request Based on $145 Million in Investment
Compare LXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXRX Lexicon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.